Shared on 31 Oct 25
Analysts have raised their price target for iRhythm Technologies from $180 to $205 per share. They cite strong recent results, expanding market share, and a positive outlook for the company's Zio Monitor platform as reasons for the increase.
Shared on 17 Oct 25
Fair value Increased 3.80%Population Health And EHR Integration Will Redefine Remote Cardiac Care
iRhythm Technologies' analyst price target has increased from $186 to approximately $193. Analysts point to healthy revenue growth, expanded market reach, and positive physician feedback as drivers behind the upward revision.
Shared on 03 Oct 25
Fair value Increased 1.85%Population Health And EHR Integration Will Redefine Remote Cardiac Care
The consensus analyst price target for iRhythm Technologies has increased modestly from $182.62 to $186.00. Analysts cite positive physician feedback and expected market expansion as key drivers for their outlook.
Shared on 27 Aug 25
Fair value Increased 2.16%Population Health And EHR Integration Will Redefine Remote Cardiac Care
The consensus analyst price target for iRhythm Technologies has increased to $181.62, driven by a proposed CMS reimbursement boost, robust MyZio app growth, management’s confidence in market share gains, and progress on FDA remediation, reflecting improved fundamentals and growth visibility. Analyst Commentary Proposed CMS Physician Fee Schedule includes a low-single digit reimbursement boost for mobile cardiac telemetry, reversing previous larger cuts and providing greater payment visibility.
Shared on 02 Aug 25
Fair value Increased 22%Population Health And EHR Integration Will Redefine Remote Cardiac Care
The upward revision in iRhythm Technologies’ consensus price target reflects improved net profit margin and a substantially lower future P/E multiple, raising the fair value estimate from $146.83 to $159.83. What's in the News iRhythm Technologies issued full-year 2025 revenue guidance of $720–$730 million.